These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26693096)

  • 1. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
    Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
    Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
    Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Int J Breast Cancer; 2015; 2015():240750. PubMed ID: 26078883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Front Oncol; 2022; 12():865292. PubMed ID: 35860587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
    Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
    JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Shor A; Tremblay G
    Cancer Manag Res; 2018; 10():1015-1025. PubMed ID: 29765249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
    Wood R; Mitra D; de Courcy J; Iyer S
    Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.
    Cuyún Carter G; Mohanty M; Stenger K; Morato Guimaraes C; Singuru S; Basa P; Singh S; Tongbram V; Kuemmel S; Guarneri V; Tolaney SM
    Cancer Manag Res; 2021; 13():6537-6566. PubMed ID: 34447271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.
    Upadhyay R; Klamer BG; Perlow HK; White JR; Bazan JG; Jhawar SR; Blakaj DM; Grecula JC; Arnett A; Mestres-Villanueva MA; Healy EH; Thomas EM; Chakravarti A; Raval RR; Lustberg M; Williams NO; Palmer JD; Beyer SJ
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
    Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
    J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study.
    Li D; Jin Y; Lin M; Zeng C; Guo Q; Liu Y; Zhang J
    Cancer Med; 2024 Feb; 13(4):e6762. PubMed ID: 38457252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.